One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Clinical trial design: time to accelerate the pace of change?
doi : 10.1016/S2665-9913(23)00011-5
Volume 5, Issue 2, February 2023, Page e59
Navigating use of rituximab during the COVID-19 pandemic
doi : 10.1016/S2665-9913(23)00005-X
Volume 5, Issue 2, February 2023, Pages e63-e64
Clinical medical education under circumstances of war
doi : 10.1016/S2665-9913(23)00009-7
Volume 5, Issue 2, February 2023, Page e65
Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study
doi : 10.1016/S2665-9913(23)00004-8
Volume 5, Issue 2, February 2023, Pages e88-e98
Pseudoxanthomatous rheumatoid nodule
doi : 10.1016/S2665-9913(21)00355-6
Volume 5, Issue 2, February 2023, Page e110
Clinical trial design: time to accelerate the pace of change?
doi : 10.1016/S2665-9913(23)00011-5
Volume 5, Issue 2, February 2023, Page e59
Preventing myofibre necrosis in immune-mediated necrotising myopathy—is complement inhibition effective?
Vidya Sadanand Limaye a b
Predicting rheumatoid arthritis-associated interstitial lung disease: filling the void
David Hutchinson a
Navigating use of rituximab during the COVID-19 pandemic
doi : 10.1016/S2665-9913(23)00005-X
Volume 5, Issue 2, February 2023, Pages e63-e64
Clinical medical education under circumstances of war
doi : 10.1016/S2665-9913(23)00009-7
Volume 5, Issue 2, February 2023, Page e65
Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial
Andrew L Mammen MD a b, Prof Anthony A Amato MD c, Prof Mazen M Dimachkie MD d, Prof Hector Chinoy PhD e f, Yessar Hussain MD h, James B Lilleker PhD g i, Iago Pinal-Fernandez MD a b, Yves Allenbach MD j k, Prof Babak Boroojerdi MD l, Mark Vanderkelen MD m, Eumorphia Maria Delicha PhD m, Harold Koendgen MD n, Ramin Farzaneh-Far MD o, Petra W Duda MD PhD o, Camil Sayegh PhD o, Prof Olivier Benveniste MD j k
Autoantibodies against citrullinated and native proteins and prediction of rheumatoid arthritis-associated interstitial lung disease: a nested case–control study
Vanessa L Kronzer MD a, Keigo Hayashi PhD c, Kazuki Yoshida MD c, Prof John M Davis III MD a, Gregory C McDermott MD c, Weixing Huang MSPH c, Paul F Dellaripa MD c, Jing Cui PhD c, Vivi Feathers MS c, Ritu R Gill MD f, Prof Hiroto Hatabu MD d, Mizuki Nishino MD d g, Rachel Blaustein BS c, Prof Cynthia S Crowson PhD a b, Prof William H Robinson MD h i, Jeremy Sokolove MD h i, Katherine P Liao MD c, Prof Michael E Weinblatt MD c, Nancy A Shadick MD c, Tracy J Doyle MD e †…Jeffrey A Sparks MD c â€
Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study
doi : 10.1016/S2665-9913(23)00004-8
Volume 5, Issue 2, February 2023, Pages e88-e98
Brain mapping inflammatory-arthritis-related fatigue in the pursuit of novel therapeutics
Kristian Stefanov BSc a, Salim Al-Wasity PhD a b, Joel T Parkinson PhD a, Gordon D Waiter PhD c, Prof Jonathan Cavanagh MD a, Prof Neil Basu MD a
Pseudoxanthomatous rheumatoid nodule
doi : 10.1016/S2665-9913(21)00355-6
Volume 5, Issue 2, February 2023, Page e110
Clinical trial design: time to accelerate the pace of change?
doi : 10.1016/S2665-9913(23)00011-5
Volume 5, Issue 2, February 2023, Page e59
Preventing myofibre necrosis in immune-mediated necrotising myopathy—is complement inhibition effective?
Vidya Sadanand Limaye a b
Predicting rheumatoid arthritis-associated interstitial lung disease: filling the void
David Hutchinson a
Navigating use of rituximab during the COVID-19 pandemic
doi : 10.1016/S2665-9913(23)00005-X
Volume 5, Issue 2, February 2023, Pages e63-e64
Clinical medical education under circumstances of war
doi : 10.1016/S2665-9913(23)00009-7
Volume 5, Issue 2, February 2023, Page e65
Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial
Andrew L Mammen MD a b, Prof Anthony A Amato MD c, Prof Mazen M Dimachkie MD d, Prof Hector Chinoy PhD e f, Yessar Hussain MD h, James B Lilleker PhD g i, Iago Pinal-Fernandez MD a b, Yves Allenbach MD j k, Prof Babak Boroojerdi MD l, Mark Vanderkelen MD m, Eumorphia Maria Delicha PhD m, Harold Koendgen MD n, Ramin Farzaneh-Far MD o, Petra W Duda MD PhD o, Camil Sayegh PhD o, Prof Olivier Benveniste MD j k
Autoantibodies against citrullinated and native proteins and prediction of rheumatoid arthritis-associated interstitial lung disease: a nested case–control study
Vanessa L Kronzer MD a, Keigo Hayashi PhD c, Kazuki Yoshida MD c, Prof John M Davis III MD a, Gregory C McDermott MD c, Weixing Huang MSPH c, Paul F Dellaripa MD c, Jing Cui PhD c, Vivi Feathers MS c, Ritu R Gill MD f, Prof Hiroto Hatabu MD d, Mizuki Nishino MD d g, Rachel Blaustein BS c, Prof Cynthia S Crowson PhD a b, Prof William H Robinson MD h i, Jeremy Sokolove MD h i, Katherine P Liao MD c, Prof Michael E Weinblatt MD c, Nancy A Shadick MD c, Tracy J Doyle MD e †…Jeffrey A Sparks MD c â€
Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study
doi : 10.1016/S2665-9913(23)00004-8
Volume 5, Issue 2, February 2023, Pages e88-e98
Brain mapping inflammatory-arthritis-related fatigue in the pursuit of novel therapeutics
Kristian Stefanov BSc a, Salim Al-Wasity PhD a b, Joel T Parkinson PhD a, Gordon D Waiter PhD c, Prof Jonathan Cavanagh MD a, Prof Neil Basu MD a
Pseudoxanthomatous rheumatoid nodule
doi : 10.1016/S2665-9913(21)00355-6
Volume 5, Issue 2, February 2023, Page e110
